Mersana Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Rhea-AI Summary

Mersana Therapeutics, focused on developing antibody drug conjugates (ADCs), will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 10:40 a.m. ET. This event will be accessible via a live webcast on their website, with an archived replay available for 30 days. The company is advancing its lead ADC, upifitamab rilsodotin (UpRi), for platinum-resistant ovarian cancer, along with other promising candidates using its proprietary platforms.

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) --  Mersana Therapeutics, Inc., (NASDAQ: MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the Company’s management team will participate in a fireside chat at the 11^th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 10:40 a.m. ET.  

A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 30 days following the presentation.

About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registration strategy in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1 umbrella study in combination with other ovarian cancer therapies. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines. Mersana Therapeutics was recently named among the 2021 Top Places to Work in Massachusetts by the Boston Globe. The Company routinely posts information that may be useful to investors on the “Investors and Media” section of our website at www.mersana.com.

Contact:

Investor & Media Contact
James Salierno, 617-498-0020
jsalierno@mersana.com

FAQ

What event will Mersana Therapeutics participate in on February 17, 2022?

Mersana Therapeutics will participate in the 11th Annual SVB Leerink Global Healthcare Conference.

What time is Mersana's presentation at the SVB Leerink Conference?

Mersana's presentation is scheduled for 10:40 a.m. ET on February 17, 2022.

Where can I watch Mersana Therapeutics' presentation?

You can watch Mersana Therapeutics' presentation via a live webcast on their website.

What is the main product candidate of Mersana Therapeutics?

Mersana's main product candidate is upifitamab rilsodotin (UpRi), targeting platinum-resistant ovarian cancer.

What platforms does Mersana Therapeutics use for developing ADCs?

Mersana Therapeutics uses its proprietary Dolaflexin and Immunosynthen platforms to develop ADCs.